2012-10-09 00:22:34 - Recently published research from Global Markets Direct, "Octapharma AG - Product Pipeline Review - 2012", is now available at Fast Market Research

Global Market Direct's pharmaceuticals report, "Octapharma AG - Product Pipeline Review - 2012" provides data on the Octapharma AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Octapharma AG's corporate website, SEC filings, investor presentations and featured press releases, both from Octapharma AG and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

* Octapharma AG - Brief Octapharma AG overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of Octapharma AG human therapeutic division.
* Overview of

pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Octapharma AG with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Octapharma AG's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.


Full Report Details at
- www.fastmr.com/prod/468569_octapharma_ag_product_pipeline_review ..


Reasons to buy

* Evaluate Octapharma AG's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Octapharma AG in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Octapharma AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Octapharma AG.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Octapharma AG and identify potential opportunities in those areas.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Octapharma AG Snapshot
Octapharma AG Overview
Key Information
Key Facts
Octapharma AG - Research and Development Overview
Key Therapeutic Areas
Octapharma AG - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Octapharma AG - Pipeline Products Glance
Octapharma AG - Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Octapharma AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Octapharma AG - Drug Profiles
hcl-rFVIII
Product Description
Mechanism of Action
R&D Progress
immune globulin intravenous pentetate
Product Description
Mechanism of Action
R&D Progress
NewGam
Product Description
Mechanism of Action
R&D Progress
Uniplas
Product Description
Mechanism of Action
R&D Progress
Octapharma AG - Pipeline Products by Route of Administration
Octapharma AG - Recent Pipeline Updates
Octapharma AG - Dormant Projects
Octapharma AG - Company Statement
Octapharma AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Octapharma AG - Key Manufacturing Facilities
Octapharma AG, Recent Developments
Octapharma AG- Press Release
Jun 26, 2012: Octapharma USA Expands Access To Octagam 5% For Participating 340B Healthcare Facilities
Feb 27, 2012: Octapharma USA Submits BLA For octaplasLG
Sep 24, 2009: Octapharma submits BLA To US FDA For Octagam 10%
Sep 09, 2009: The UK Blood Advisory Group (SaBTO) Recommends Variant Creutzfeld Jacob Disease (vCJD) Risk-Reduction Strategy For Fresh Frozen Plasma (FFP) Octapharma Develop OctaplasLG To Offer A Solution
Aug 26, 2009: Octapharma Targeting The Major Risk Of Hemophilia Treatment - FVIII Antibodies
Feb 11, 2009: Octapharma Starts Ohase II Clinical Study In Alzheimer's Disease with Octagam 10%
Financial Deals Landscape
Octapharma AG, Deals Summary
Octapharma AG, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Octapharma Acquires 33 Plasma Centers From International BioResources
Partnerships
BAC Enters Into An Development Agreement With Octapharma
BAC Enters Into Co-Development Agreement With Octapharma
Licensing Agreements
Octapharma Enters Into License Agreement With Fresenius Kabi
BAC Extends Licensing Agreement With Octapharma
BAC Enters Into Licensing Agreement With Octapharma
Acquisition
Diagnostica Stago Acquires Life Diagnostics From Octapharma
Octapharma Acquires PVG From German Red Cross
Octapharma Acquires Deutsche Gesellschaft fur Humanplasma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Octapharma AG, Key Information
Octapharma AG, Key Facts
Octapharma AG - Pipeline by Indication, 2012
Octapharma AG - Pipeline by Stage of Development, 2012
Octapharma AG - Monotherapy Products in Pipeline, 2012
Octapharma AG - Filed, 2012
Octapharma AG - Phase III, 2012
Octapharma AG - Phase II, 2012
Octapharma AG - Pipeline By Route of Administration, 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468569&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.